Thomas N. Rabe (born February 18, 1951 in Heidelberg) is a German professor for gynaecology and obstetrics at the University Hospital Heidelberg. He is author of several scientific publications and reference books.
Rabe earned his medical degree in Heidelberg. Since 1983 he has been a specialist in gynaecology and obstetrics. His research was focused on the steroid metabolism of the placenta, new methods of family planning, hormone therapy, and the development of computer-based teaching systems. After his professorship for gynaecology and obstetrics in 1991, he became attending physician at the university hospital and at the department for gynaecology, endocrinology, and fertility issues.
Between 1995 and 1999 Rabe was responsible for the scientific activities of the Collaborating Centres WHO (Genf) at the university's hospital for women. He also belongs to the editorial staff of several national and international trade journals.
Rabe is the grandson of John Rabe and advocates coming to terms with the history between China and Japan.With the support of his family he founded the "John Rabe Communication Centre", which is dedicated to continue his grandfather John Rabe's vision of peace.
In addition to his international contacts with various clinics and hospitals, Rabe is also member of the International Council at the Austrian Service Abroad.
Gynaecology or gynecology is the medical practice dealing with the health of the female reproductive system. Almost all modern gynaecologists are also obstetricians. In many areas, the specialities of gynaecology and obstetrics overlap.
Emeritus Professor Sittampalam Shanmugaratnam, also known as Shan Ratnam, was a Singaporean obstetrician and gynaecologist.
Stuart Campbell DSc FRCPEd FRCOG FACOG, was born in Glasgow, Scotland, and graduated from the medical school of Glasgow University. During his training he worked with Ian Donald, who had published some of the first papers on the use of ultrasound in obstetrics.
Dame Anne Louise McIlroy, known as Louise McIlroy, was a distinguished and honoured Irish-born British physician, specialising in obstetrics and gynaecology. She was both the first woman to be awarded a Doctor of Medicine (MD) degree and to register as a research student at the University of Glasgow. She was also the first woman medical professor in the United Kingdom.
The Kahun Gynaecological Papyrus is the oldest known medical text in Egypt, although not the oldest in the world as in Philadelphia museum a Sumerian medical clay tablet from 3rd millennium is preserved. Dated to c. 1800 BCE, it deals with women's health—gynaecological diseases, fertility, pregnancy, contraception, etc.
Combined injectable contraceptives (CICs) are a form of hormonal birth control for women. They consist of monthly injections of combined formulations containing an estrogen and a progestin to prevent pregnancy.
Isaac Baker Brown was a prominent 19th-century English gynaecologist and obstetrical surgeon. He had a reputation as a specialist in the diseases of women and advocated certain surgical procedures, including clitoridectomies, as cures for epilepsy and hysteria. His career ended when he was accused of performing these procedures without consent of the patients. He was subsequently expelled from the Obstetrical Society of London.
Azastene (INN, USAN) (developmental code name WIN-17625) is a steroidogenesis inhibitor described as a contraceptive, luteolytic, and abortifacient which was never marketed. It acts as a competitive inhibitor of 3β-hydroxysteroid dehydrogenase (IC50 = 1 μM), and thereby inhibiting the formation of progesterone, corticosteroids, androgens, and estrogens. Due to inhibition of corticosteroid synthesis, azastene is immunosuppressive.
Hydroxyprogesterone acetate (OHPA), sold under the brand name Prodox, is an orally active progestin related to hydroxyprogesterone caproate (OHPC) which has been used in clinical and veterinary medicine. It has reportedly also been used in birth control pills.
Anordrin, also known as 2α,17α-diethynyl-A-nor-5α-androstane-2β,17β-diol dipropionate, is a synthetic, steroidal selective estrogen receptor modulator (SERM) which is used in China as an emergency contraceptive. It is the most commonly used emergency contraceptive in China. The drug is marketed in a combination formulation with mifepristone under the brand name Zi Yun. Anordrin has not been studied for use or marketed outside of China. It has been used in China since the 1970s.
Ethynerone, also known as 17α-(2-chloroethynyl)estra-4,9-dien-17β-ol-3-one, is a steroidal progestin of the 19-nortestosterone group that was first reported in 1961 but was never marketed. Under the developmental code name MK-665, it was studied in combination with mestranol as an oral contraceptive. Development of the drug was discontinued due to concerns surrounding toxicity findings in dogs. It is a chloroethynylated derivative of norethisterone.
Oxogestone phenpropionate, also known as xinogestone, as well as 20β-hydroxy-19-norprogesterone 20β-(3-phenylpropionate), is a progestin related to the 19-norprogesterone derivatives which was developed as an injectable hormonal contraceptive, specifically a progestogen-only injectable contraceptive, in the 1960s and early 1970s but was never marketed. It was studied at a dose of 50 to 75 mg once a month by intramuscular injection but was associated with a high failure rate with this regimen and was not further developed. OPP is the 20β-(3-phenylpropionate) ester of oxogestone, which, similarly, was never marketed.
Chloroethynylnorgestrel is a steroidal progestin of the 19-nortestosterone group related to norgestrel that was investigated as an oral contraceptive in the 1970s but was never marketed.
Sven Becker is a German gynaecologist, gynaecologic surgeon, and oncologist.
Levonorgestrel butanoate (LNG-B), or levonorgestrel 17β-butanoate, is a steroidal progestin of the 19-nortestosterone group which was developed by the World Health Organization (WHO) in collaboration with the Contraceptive Development Branch (CDB) of the National Institute of Child Health and Human Development as a long-acting injectable contraceptive. It is the C17β butanoate ester of levonorgestrel, and acts as a prodrug of levonorgestrel in the body. The drug is at or beyond the phase III stage of clinical development, but has not been marketed at this time. It was first described in the literature, by the WHO, in 1983, and has been under investigation for potential clinical use since then.
John R. Fraser FRCOG (1890-1959) was a physician on the staff of the Obstetric and Gynaecological Department at McGill and in 1929, professor, chairman and head of department at McGill and Royal Victoria Hospital.
Lynestrenol phenylpropionate (LPP), also known as ethynylestrenol phenylpropionate, is a progestin and a progestogen ester which was developed for potential use as a progestogen-only injectable contraceptive by Organon but was never marketed. It was assessed at doses of 25 to 75 mg in an oil solution once a month by intramuscular injection. LPP was associated with high contraceptive failure at the low dose and with poor cycle control. The medication was found to produce estrogenic effects in the endometrium in women due to transformation into estrogenic metabolites.
Levonorgestrel cyclobutylcarboxylate is a progestin and a progestogen ester which was studied for potential use as an injectable hormonal contraceptive but was never marketed. It was developed by the World Health Organization's Special Programme on Human Reproduction in the 1980s. Analogues of levonorgestrel cyclobutylcarboxylate include levonorgestrel butanoate (HRP-002) and levonorgestrel cyclopropylcarboxylate (HRP-003).
Levonorgestrel cyclopropylcarboxylate, or levonorgestrel 17β-cyclopropylcarboxylate, is a progestin and a progestogen ester which was studied for potential use as an injectable hormonal contraceptive but was never marketed. It was developed by the World Health Organization's Special Programme on Human Reproduction in the 1980s. Analogues of levonorgestrel cyclopropylcarboxylate include levonorgestrel cyclobutylcarboxylate (HRP-001) and levonorgestrel butanoate (HRP-002).
Rolf Kreienberg was a German gynaecologist and obstetrician.